Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). GlaxoSmithKline's share price for the quarter that ended in Sep. 2016 was E£9.32. GlaxoSmithKline's Shares Outstanding (EOP) for the quarter that ended in Sep. 2016 was 84 Mil. Therefore, GlaxoSmithKline's market cap for the quarter that ended in Sep. 2016 was E£778 Mil.
GlaxoSmithKline's quarterly market cap
increased
from Mar. 2016 (E£756 Mil) to Jun. 2016 (E£778 Mil) but then
stayed the same
from Jun. 2016 (E£778 Mil) to Sep. 2016 (E£778 Mil).
GlaxoSmithKline's annual market cap
declined
from Dec. 2013 (E£1,234 Mil) to Dec. 2014 (E£985 Mil) and
declined
from Dec. 2014 (E£985 Mil) to Dec. 2015 (E£887 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GlaxoSmithKline's Enterprise Value for Today is E£778 Mil.
GlaxoSmithKline (CAI:BIOC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
GlaxoSmithKline Market Cap Related Terms
GlaxoSmithKline Market Cap Historical Data
* Premium members only.
The historical data trend for GlaxoSmithKline's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GlaxoSmithKline's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline's Market Cap distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
GlaxoSmithKline's Market Cap for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline (CAI:BIOC) has a Market Cap of E£778 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Market Cap too high?
GlaxoSmithKline's current Market Cap is E£778 Mil.
How does GlaxoSmithKline's Market Cap compare to PRPH?
GlaxoSmithKline's Market Cap of E£778 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 220.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 220.02, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GlaxoSmithKline and its competitors. For the Drug Manufacturers industry, the median Market Cap is 220.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline's current Market Cap is E£778 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Market Cap of E£778 Mil. The current Market Cap is E£778 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Market Cap is E£778 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:BIOC has been successfully added to your 